MedElevator
Войти в исследования JHEP reports : innovation in hepatology · 2025
Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lamatsch Sven, Hassan Mohsin, Kappert Kai, Berger Hilmar, Bai Qingquan, Zhao Zhengyang, Walia Nirbaanjot, De La Peña-Ramirez Carlos, Mohr Raphael, Demir Münevver, Wang Juan, Artusa Fabian, Sittner Richard, Andreola Fausto, Veelken Rhea, van Boemmel Florian, Schumacher Jonas, Aehling Niklas, Fischer Janett, Mookerjee Rajeshwar, Hu Tianhui, Berg Thomas, Jalan Rajiv, Tacke Frank, Kumar Pavitra, Engelmann Cornelius
Аннотация
BACKGROUND & AIMS: Cirrhosis poses a significant healthcare burden, with decompensation and acute-on-chronic liver failure (ACLF) resulting in high morbidity and mortality. Reliable biomarkers of disease progression are urgently needed. Urokinase plasminogen activator receptor (uPAR) and its soluble form (suPAR) are linked to systemic inflammation in liver disease. This study aims to evaluate suPAR as a prognostic marker and its role in chronic liver disease.
METHODS: SuPAR levels were measured in a derivation cohort (n = 178) and a validation cohort (n = 197) from two centers, including healthy controls and patients with cirrhosis, acute decompensation, and ACLF. In a mouse model using carbon tetrachloride and lipopolysaccharide, suPAR levels correlated with liver uPAR expression. Single-cell RNA sequencing was used to analyze uPAR expression in immune cells from healthy controls and from patients with HBV-related cirrhosis.
RESULTS: SuPAR levels correlated with disease severity markers, including creatinine, bilirubin, albumin, international normalized ratio, MELD score, and hospitalization duration (all p <0.001). They were associated with higher in-hospital mortality (p = 0.02), intensive care unit treatment (p <0.001), 90-day mortality (p = 0.003), and ACLF progression (p = 0.014). SuPAR levels ≥14.0 ng/ml independently predicted 90-day mortality in decompensated cirrhosis (hazard ratio [HR] 5.295, p = 0.015). The validation cohort confirmed these correlations, with increased 28-day (HR 9.589, p <0.001) and 90-day (HR 7.899, p <0.001) mortality. In mice, suPAR and liver uPAR expression were significantly higher in acute-on-chronic injury compared with chronic injury and control groups. Single-cell RNA sequencing in human liver immune cells revealed increased PLAUR expression in monocytes, macrophages, and dendritic cells in HBV-induced cirrhosis.
CONCLUSIONS: SuPAR is a potential biomarker for predicting outcomes in acute decompensation, reflecting both systemic and liver-specific inflammation. Further studies are needed to clarify the role of uPAR-expressing cells in disease progression.
IMPACT AND IMPLICATIONS: Our study identifies soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of liver-derived systemic inflammation that is clinically relevant for predicting adverse outcomes in decompensated cirrhosis and is associated with disease progression, organ dysfunction, and mortality. Systemic suPAR levels ≥14.0 ng/ml independently predicted 90-day mortality in patients with decompensated cirrhosis across two independent cohorts. Accurate outcome prediction is crucial for developing tailored, personalized treatments in advanced chronic liver disease, and suPAR, as an independent predictor of short-term mortality and disease progression, may complement established scoring systems such as MELD.
METHODS: SuPAR levels were measured in a derivation cohort (n = 178) and a validation cohort (n = 197) from two centers, including healthy controls and patients with cirrhosis, acute decompensation, and ACLF. In a mouse model using carbon tetrachloride and lipopolysaccharide, suPAR levels correlated with liver uPAR expression. Single-cell RNA sequencing was used to analyze uPAR expression in immune cells from healthy controls and from patients with HBV-related cirrhosis.
RESULTS: SuPAR levels correlated with disease severity markers, including creatinine, bilirubin, albumin, international normalized ratio, MELD score, and hospitalization duration (all p <0.001). They were associated with higher in-hospital mortality (p = 0.02), intensive care unit treatment (p <0.001), 90-day mortality (p = 0.003), and ACLF progression (p = 0.014). SuPAR levels ≥14.0 ng/ml independently predicted 90-day mortality in decompensated cirrhosis (hazard ratio [HR] 5.295, p = 0.015). The validation cohort confirmed these correlations, with increased 28-day (HR 9.589, p <0.001) and 90-day (HR 7.899, p <0.001) mortality. In mice, suPAR and liver uPAR expression were significantly higher in acute-on-chronic injury compared with chronic injury and control groups. Single-cell RNA sequencing in human liver immune cells revealed increased PLAUR expression in monocytes, macrophages, and dendritic cells in HBV-induced cirrhosis.
CONCLUSIONS: SuPAR is a potential biomarker for predicting outcomes in acute decompensation, reflecting both systemic and liver-specific inflammation. Further studies are needed to clarify the role of uPAR-expressing cells in disease progression.
IMPACT AND IMPLICATIONS: Our study identifies soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of liver-derived systemic inflammation that is clinically relevant for predicting adverse outcomes in decompensated cirrhosis and is associated with disease progression, organ dysfunction, and mortality. Systemic suPAR levels ≥14.0 ng/ml independently predicted 90-day mortality in patients with decompensated cirrhosis across two independent cohorts. Accurate outcome prediction is crucial for developing tailored, personalized treatments in advanced chronic liver disease, and suPAR, as an independent predictor of short-term mortality and disease progression, may complement established scoring systems such as MELD.